Claim OwnershipOncology On The Go
Subscribed: 37Played: 402
Subscribe
Description
Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences.
As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
To learn more, you can also visit us on Facebook, Twitter, and LinkedIn!
As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
To learn more, you can also visit us on Facebook, Twitter, and LinkedIn!
170 Episodes
Reverse
As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma.
In the video series, Cheson and Park discussed the following:
· Overview of relapsed/refractory follicular lymphoma and available treatment options
· Tazemetostat trial data and propensity score-matched analysis
· Role of tazemetostat treatment moving forward
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma.
In the video series, Richardson and Gasparetto discussed the following:
· Overview of proteasome inhibitor therapy in multiple myeloma
· Real-world data with proteasome inhibitors
· The phase 3 TOURMALINE-MM1 trial (NCT01564537) of ixazomib therapy in relapsed/refractory multiple myeloma
· Ixazomib plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
Be sure to tune in to other videos in the CancerNetwork® Between the Lines™ series.
As part of its OncView™ program, CancerNetwork hosted a discussion Lori Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital in Boston, who shared her perspective on updates in the treatment of second-line radioiodine-refractory differentiated thyroid cancer, or DTC.
In the video series, some of the content discussed included:
· Presentation and Disease Course of Differentiated Thyroid Cancer
· Frontline Treatment Options for RAI-refractory DTC
· Treatment Options in RAI-refractory DTC in Second Line and Beyond
· Facing Unmet Needs and Ongoing Trials in RR-DTC
To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of the Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, of the O’Neal Comprehensive Cancer Center, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, who shared their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and commented on emerging data in the field.
To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
OncView™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib.
In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following:
Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design
Efficacy Data From the EXCLAIM Cohort in mNSCLC
EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC
EXCLAIM Cohort in mNSCLC: Treatment Selection and Management
mNSCLC: Biomarker Testing and Patient Adherence to TKIs
Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.
In the video series, Piotrowska discussed the following:
· Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions
· Testing for the EGFR Exon 20 Insertion
· Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC
· Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC
· Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC
· Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC
· Unmet Needs and Future Directions
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Liliana Bustamante, MD, hematologist and medical oncologist at Florida Cancer Specialists in Fort Myers, Florida and Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at the Moffitt Cancer Center in Tampa, Florida, about the prognostic potential of circulating tumor DNA (ctDNA) as a biomarker for patients with oligometastatic colorectal cancer.
In the video series, Bustamante and Kim discussed the following:
· Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
· Key Takeaways: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
· ctDNA as a Biomarker in CRC
· ctDNA Assays in CRC: Interpreting Clinical Findings
· ctDNA Assays in CRC: Impact on Clinical Practice
· Next Steps in Using ctDNA as a Biomarker in CRC
· Recap: Prognostic Potential of ctDNA for Oligometastatic Colorectal Cancer
To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly.
In the video series, Kirkwood discussed the following:
· Treatment Options for Melanoma
· Considerations for Immunotherapy Use When Treating Melanoma
· Monitoring Responses to Melanoma Therapy
· Pseudoprogression in Melanoma Therapy
· ctDNA for Melanoma Treatment Monitoring
· Using ctDNA to Monitor Patients With Melanoma
· Taking Drug Holidays Amidst Melanoma Therapy
· Duration of Treatment for Melanoma
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
As part of its OncView™ video series, CancerNetwork® spoke with Roy Herbst, MD, PhD, chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, about currently available treatment options and strategies in immunotherapy for treating non–small cell lung cancer (NSCLC).
In the video series, Herbst discussed the following:
· Treatment Options in Non–Small Cell Lung Cancer
· Monitoring Response to Therapy in NSCLC
· Role of ctDNA in Monitoring Treatment Response in NSCLC
· Clinical Decision-Making in NSCLC
· Recap: Monitoring With ctDNA for Immunotherapy Response in Lung Cancer
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC).
In the video series, Bazhenova and Albrecht discussed the following:
· Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC
· EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data
· Experts in Treating EGFR-Positive NSCLC Compare Randomized Trials and Real-World Studies
· EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions
· Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC
· Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC
· Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC
To watch more videos in CancerNetwork®’s Between the Lines™ series, visit cancernetwork.com/between-the-lines.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the previous podcast episodes in this series:
· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer
· Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
· Episode 3: Practical Considerations for Small Cell Lung Cancer Therapeutic Options
In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the previous podcast episodes in this series:
· Episode 1: First-Line Therapeutic Options in Small Cell Lung Cancer
· Episode 2: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.
In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes.
In the video series, Batlevi discussed the following:
· Current Treatment Options and Considerations for Relapsed/Refractory Follicular Lymphoma
· Third-Line Therapies in R/R FL
· Use of Tazemetostat in R/R FL
· Sequencing Changes in R/R FL Therapies
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy.
To watch more videos in CancerNetwork’s Between the Lines series, visit cancernetwork.com.
For the final installment of a 3-part relapsed/refractory DLBCL series, CancerNetwork heard from Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, and Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center.
These lymphoma experts spoke about their thoughts on data from the L-MIND trial, when to implement CAR-T cell therapies for patients, the role of Selinexor in treating patients, and a host of other important ideas.
Don’t forget to subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available. Be sure to check out the 2 other installments of this 3-part DLBCL series on rituximab rechallenging and different treatment regimens.
As part of its OncView™ video series, CancerNetwork® spoke with Javier Munoz, MD, MS, FACP, from the Mayo Clinic in Phoenix, Arizona, about updates in therapies of relapsed/refractory follicular lymphoma.
In the video series, Javier Munoz, MD, MS, FACP, discussed the following:
· Current Treatment Options for Relapsed/Refractory Follicular Lymphoma
· Factors in Choosing R/R FL Treatments
· Treatment Options for Third-Line R/R FL
· Use of Tazemetostat for R/R FL
· Changes in Sequencing of R/R FL Therapies
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer.
In the video series, Lee Schwartzberg, MD, FACP, discussed the following:
· Extended Adjuvant Therapy for HR+ Breast Cancer
· Molecular Biomarkers for HR+ Breast Cancer
· Role of Genomic Testing in HR Positive Breast Cancer
· Appropriateness for Genomic Testing in HR+ Breast Cancer
· Integration of Genomic Testing into NCCN Guidelines
· Current Recommendations for Genomic Testing in HR+ Breast Cancer
· Treatment Limitations in HR+ Breast Cancer
To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
CancerNetwork spoke with Kami Maddocks MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University, about CD-19 directed agents, avoiding rechallenging with rituximab, and second-line outcomes for transplant-ineligible patients with diffuse large B-cell lymphoma (DLBCL).
Visit cancernetwork.com to check out the first episode of this 3-part series here.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
Download from Google Play
Download from App Store
United States